{"protocolSection": {"identificationModule": {"nctId": "NCT03532490", "orgStudyIdInfo": {"id": "IRB00156697"}, "secondaryIdInfos": [{"id": "R34HL135361", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/R34HL135361"}], "organization": {"fullName": "Johns Hopkins University", "class": "OTHER"}, "briefTitle": "Trial of Roflumilast in Asthma Management (TRIM)", "officialTitle": "Trial of Roflumilast in Asthma Management (TRIM)", "acronym": "TRIM"}, "statusModule": {"statusVerifiedDate": "2022-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-08-03", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-07-30", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-07-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-05-09", "studyFirstSubmitQcDate": "2018-05-09", "studyFirstPostDateStruct": {"date": "2018-05-22", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-07-01", "resultsFirstSubmitQcDate": "2022-09-09", "resultsFirstPostDateStruct": {"date": "2022-10-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-09-09", "lastUpdatePostDateStruct": {"date": "2022-10-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Johns Hopkins University", "class": "OTHER"}, "collaborators": [{"name": "American Lung Association", "class": "OTHER"}, {"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "There are currently no treatments to specifically target asthma in obese adults. This pilot study is being conducted to investigate how effective roflumilast is in treating asthma in participants that have a higher BMI. Roflumilast can induce weight loss, which may lead to improved asthma control.\n\nThe primary objective of TRIM is to perform a pilot placebo-controlled trial of roflumilast for the treatment of poorly controlled obese asthmatics.", "detailedDescription": "TRIM is a 24 week, randomized, double-masked, placebo controlled trial that will enroll 38 participants.\n\nThis study will be take place in seven centers of the American Lung Association- Airways Clinical Research Centers (ALA-ACRC). The centers include: Northwestern University Feinberg School of Medicine, Mount Sinai Icahn School of Medicine, Duke University, University of Arizona, the University of Vermont, The University of Alabama Lung Health Center, and University of Illinois Breathe Chicago Center. Johns Hopkins University will be the Data Coordinating Center (DCC) for the trial."}, "conditionsModule": {"conditions": ["Asthma", "Obesity"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 38, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Roflumilast 500 mcg oral tablet", "type": "ACTIVE_COMPARATOR", "description": "500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.", "interventionNames": ["Drug: Roflumilast 500 Mcg Oral Tablet"]}, {"label": "Placebo oral tablet", "type": "PLACEBO_COMPARATOR", "description": "500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.", "interventionNames": ["Drug: Placebo oral capsule"]}], "interventions": [{"type": "DRUG", "name": "Roflumilast 500 Mcg Oral Tablet", "description": "The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.", "armGroupLabels": ["Roflumilast 500 mcg oral tablet"], "otherNames": ["Daliresp"]}, {"type": "DRUG", "name": "Placebo oral capsule", "description": "The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.", "armGroupLabels": ["Placebo oral tablet"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Asthma Control Test Score", "description": "The Asthma Control Test was designed to help participants describe their asthma and how it affects how they feel and what they are able to do. They choose a response based on their asthma within the last 4 weeks. Participants select how many times per week they experience different asthma symptoms and how often they had to use a rescue inhaler or nebulizer. There are 5 questions with 5 responses; 1 meaning their asthma is not well controlled or they had symptoms more frequently, through 5 meaning they feel their asthma is well controlled or they do not experience any symptoms.\n\nThe primary outcome is an unadjusted comparison of 24 week change in Asthma Control Test scores between the treatment groups.", "timeFrame": "Baseline and 24 weeks"}], "secondaryOutcomes": [{"measure": "Change in Weight", "description": "Weight change measured in kilograms (kg).", "timeFrame": "Baseline and 24 weeks"}, {"measure": "Change in Asthma Symptom Utility Index (ASUI)", "description": "A 10-item questionnaire, patient preference-based scale assessing frequency and severity of selected asthma-related symptoms and treatment side effects, for use in clinical trials and cost-effectiveness studies in asthma. Range is 0-1. Higher score is indicative of better health.", "timeFrame": "baseline and 24 weeks"}, {"measure": "Change in Gastrointestinal Symptom Rating Scale (GSRS)", "description": "It has 5 subscales (Reflux, Diarrhea, Constipation, Abdominal Pain, and Indigestion Syndrome). Subscale scores range from 1 to 7 and higher scores represent more discomfort and poor health.", "timeFrame": "Baseline and 24 weeks"}, {"measure": "Change in Generalized Anxiety Disease (GAD-7)", "description": "GAD-7 has 7 questions. The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and adding together the scores for the seven questions. The following cut-offs correlate with level of anxiety severity:\n\nScore 0-4: Minimal Anxiety Score 5-9: Mild Anxiety Score 10-14: Moderate Anxiety Score greater than 15: Severe Anxiety", "timeFrame": "baseline and 24 weeks"}, {"measure": "Change in Marks Asthma Quality of Life Questionnaire", "description": "20 items with 2 week recall. Self-administered questionnaire intended for use with adults. Respondents are asked to describe how troubling particular items have been over the past four weeks. Covers both physical and emotional impact. Range 1-4. lower score is indicative of better health", "timeFrame": "baseline and 24 weeks"}, {"measure": "Change in SF 36", "description": "The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Range 0-100. Higher score is indicative of better health.", "timeFrame": "baseline and 24 weeks"}, {"measure": "Change in PHQ9", "description": "The PHQ-9 (Patient Health Questionnaire-9) objectifies and assesses degree of depression severity via questionnaire. It has 9 questions. Range 0-27, lower score is indicate of better health.", "timeFrame": "baseline and 24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Physician diagnosis of asthma on regular prescribed controller therapy for at least 3 months\n* Previous (within five years) evidence of at least a 12% increase in forced expiratory volume at one second FEV1 after inhaling 2-4 puffs of albuterol or a positive methacholine challenge or patient reported history of improvement of asthma exacerbation after a course of systemic or inhaled corticosteroids\n* Age: \u226518 years of age\n* Obese: Body Mass Index (BMI) \\> 30 kg/m2\n* Poorly controlled asthma: Asthma Control Test (ACT) Score \\< 20, or use of rescue inhaler, on an average of\\> 2 uses/week for preceding month, or nocturnal asthma awakening, on an average of 1 or more times / week in preceding month, or emergency department (ED)/hospital visit or prednisone course for asthma in past six months.\n* Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\n* Participation in an investigational study within the past 4 weeks\n* Physician diagnosis of chronic obstructive pulmonary disease\n* Any condition that puts the participant at risk from weight loss as judged by the site physician\n* Liver cirrhosis\n* Major psychiatric disorders such as generalized anxiety disorder, major depressive disorder, history of suicidal ideation/ attempt, panic disorder, post-traumatic stress disorder, schizophrenia, schizoaffective, substance abuse or other disorders that in the opinion of the study physician that would affect study participation\n* \\> 0 time use of illicit drugs in the past 12 months\n* \\> 0 time use of cannabis in the past 12 months\n* Uncontrolled depression as defined by a score of 15 or greater on the depression questions of the Patient Health Questionnaire (PHQ-9)\n* Suicidal ideation (a score of greater than 0 on Question 9 on the PHQ-9)\n* Uncontrolled anxiety as defined by a score of 10 or greater on the anxiety questions of the Generalized Anxiety Disorder 7-item (GAD-7)\n* Pregnancy/lactation\n* Females of childbearing age who do not agree to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for the duration of the study.\n* Greater than 20 pack year smoking history, or smoking within the last 6 months.\n* History of bariatric surgery\n* Drugs metabolized by cytochrome P450 (rifampicin, phenobarbital, carbamazepine, phenytoin, erythromycin, ketoconazole, cimetidine, fluvoxamine, enoxacin, oral contraceptives containing ethinyl estradiol with gestodene).\n* Currently on roflumilast or theophylline (patient may wash out of these medications for 4 weeks prior to visit 1)\n* Intention to move out of area within the next 6 months", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Anne Dixon, MD", "affiliation": "University of Vermont", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Robert Wise, MD", "affiliation": "Johns Hopkins School of Medicine", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Alabama Lung Health Center", "city": "Birmingham", "state": "Alabama", "zip": "35294", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "University of Arizona", "city": "Tucson", "state": "Arizona", "zip": "85724", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "University of Illinois at Chicago, Breathe Chicago Center", "city": "Chicago", "state": "Illinois", "zip": "60608", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Northwestern University Feinberg School of Medicine", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Mount Sinai Icahn School of Medicine", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Duke University", "city": "Durham", "state": "North Carolina", "zip": "27705", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "University of Vermont", "city": "Colchester", "state": "Vermont", "zip": "05446", "country": "United States", "geoPoint": {"lat": 44.54394, "lon": -73.14791}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Recruitment began in July 2018 and last participant visit was completed on July 2021. Participants were recruited from 7 clinical sites: University of Vermont, University of Arizona, Duke, University of Illinois, Chicago, Northwestern, University of Alabama, and Mount Sinai.", "groups": [{"id": "FG000", "title": "Placebo Oral Tablet", "description": "500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nPlacebo oral capsule: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}, {"id": "FG001", "title": "Roflumilast 500 mcg Oral Tablet", "description": "500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nRoflumilast 500 Mcg Oral Tablet: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo Oral Tablet", "description": "500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nPlacebo oral capsule: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}, {"id": "BG001", "title": "Roflumilast 500 mcg Oral Tablet", "description": "500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nRoflumilast 500 Mcg Oral Tablet: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "38"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56", "lowerLimit": "50", "upperLimit": "63"}, {"groupId": "BG001", "value": "51", "lowerLimit": "43", "upperLimit": "59"}, {"groupId": "BG002", "value": "53", "lowerLimit": "49", "upperLimit": "60"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "33"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "33"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "16"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "17"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "38"}]}]}]}, {"title": "Smoking status", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Never", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "32"}]}, {"title": "Former", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "Age at asthma onset (years)", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14", "lowerLimit": "9", "upperLimit": "37"}, {"groupId": "BG001", "value": "21", "lowerLimit": "7", "upperLimit": "42"}, {"groupId": "BG002", "value": "21", "lowerLimit": "7", "upperLimit": "42"}]}]}]}, {"title": "Asthma Control Test at Visit 2 (V2)", "description": "Range 5-25, higher score is indicative of better health", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "19", "lowerLimit": "16", "upperLimit": "19"}, {"groupId": "BG001", "value": "17", "lowerLimit": "14", "upperLimit": "18"}, {"groupId": "BG002", "value": "17", "lowerLimit": "15", "upperLimit": "19"}]}]}]}, {"title": "Asthma Symptom Utility Index", "description": "range 0-1, higher score is indicative of better health", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": ".8", "lowerLimit": ".7", "upperLimit": ".9"}, {"groupId": "BG001", "value": ".7", "lowerLimit": ".6", "upperLimit": ".8"}, {"groupId": "BG002", "value": ".7", "lowerLimit": ".6", "upperLimit": ".8"}]}]}]}, {"title": "Marks Asthma Quality of Life", "description": "Range 1-4, lower score is indicative of better health", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.1", "lowerLimit": "1", "upperLimit": "4"}, {"groupId": "BG001", "value": "1.8", "lowerLimit": "1.6", "upperLimit": "2.4"}, {"groupId": "BG002", "value": "2", "lowerLimit": "1.5", "upperLimit": "2.5"}]}]}]}, {"title": "Patient Health Questionnaire-9", "description": "range 0-27, lower score is indicative of better health", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2", "lowerLimit": "1", "upperLimit": "4"}, {"groupId": "BG001", "value": "2", "lowerLimit": "1", "upperLimit": "3"}, {"groupId": "BG002", "value": "2", "lowerLimit": "1", "upperLimit": "4"}]}]}]}, {"title": "General Anxiety Disorder-7", "description": "range 0-27, lower score is indicative of better health", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0", "lowerLimit": "0", "upperLimit": "2"}, {"groupId": "BG001", "value": "0", "lowerLimit": "0", "upperLimit": "1"}, {"groupId": "BG002", "value": "0", "lowerLimit": "0", "upperLimit": "1"}]}]}]}, {"title": "Short form survey-36", "description": "Range 0-100, higher score is indicative of better health", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59", "lowerLimit": "46", "upperLimit": "76"}, {"groupId": "BG001", "value": "67", "lowerLimit": "52", "upperLimit": "78"}, {"groupId": "BG002", "value": "62", "lowerLimit": "47", "upperLimit": "78"}]}]}]}, {"title": "Gastrointestinal Symptom Rating Scale", "description": "range 1-7, lower score is indicative of better health", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.4", "lowerLimit": "1.2", "upperLimit": "2.1"}, {"groupId": "BG001", "value": "1.5", "lowerLimit": "1.1", "upperLimit": "1.9"}, {"groupId": "BG002", "value": "1.4", "lowerLimit": "1.1", "upperLimit": "1.9"}]}]}]}, {"title": "Forced expiratory volume at one second", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.91", "lowerLimit": "1.27", "upperLimit": "2.25"}, {"groupId": "BG001", "value": "2.17", "lowerLimit": "1.79", "upperLimit": "2.41"}, {"groupId": "BG002", "value": "2.03", "lowerLimit": "1.65", "upperLimit": "2.31"}]}]}]}, {"title": "Forced Vital Capacity", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3", "lowerLimit": "2.55", "upperLimit": "3.23"}, {"groupId": "BG001", "value": "3.08", "lowerLimit": "2.75", "upperLimit": "3.52"}, {"groupId": "BG002", "value": "3.08", "lowerLimit": "2.75", "upperLimit": "3.23"}]}]}]}, {"title": "Forced Expiratory Volume/Forced vital capacity", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "ratio", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": ".78", "lowerLimit": ".70", "upperLimit": ".83"}, {"groupId": "BG001", "value": ".76", "lowerLimit": ".69", "upperLimit": ".78"}, {"groupId": "BG002", "value": ".76", "lowerLimit": ".70", "upperLimit": ".81"}]}]}]}, {"title": "Methacholine PD20", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "microgram (mcg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "115", "lowerLimit": "14", "upperLimit": "236"}, {"groupId": "BG001", "value": "75", "lowerLimit": "37", "upperLimit": "162"}, {"groupId": "BG002", "value": "95", "lowerLimit": "14", "upperLimit": "236"}]}]}]}, {"title": "Greater than/equal to 1 unscheduled health visit for asthma in prior year", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "18"}]}]}]}, {"title": "Greater than/equal to 1 course of oral corticosteroids in prior year", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "23"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Asthma Control Test Score", "description": "The Asthma Control Test was designed to help participants describe their asthma and how it affects how they feel and what they are able to do. They choose a response based on their asthma within the last 4 weeks. Participants select how many times per week they experience different asthma symptoms and how often they had to use a rescue inhaler or nebulizer. There are 5 questions with 5 responses; 1 meaning their asthma is not well controlled or they had symptoms more frequently, through 5 meaning they feel their asthma is well controlled or they do not experience any symptoms.\n\nThe primary outcome is an unadjusted comparison of 24 week change in Asthma Control Test scores between the treatment groups.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nPlacebo oral capsule: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}, {"id": "OG001", "title": "Roflumilast", "description": "500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nRoflumilast 500 Mcg Oral Tablet: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2", "lowerLimit": ".7", "upperLimit": "3.3"}, {"groupId": "OG001", "value": "2.6", "lowerLimit": ".5", "upperLimit": "4.4"}]}]}]}, {"type": "SECONDARY", "title": "Change in Weight", "description": "Weight change measured in kilograms (kg).", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "kg", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Placebo Oral Tablet", "description": "500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nPlacebo oral capsule: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}, {"id": "OG001", "title": "Roflumilast 500 mcg Oral Tablet", "description": "500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nRoflumilast 500 Mcg Oral Tablet: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.7", "lowerLimit": "-2.9", "upperLimit": "-0.5"}, {"groupId": "OG001", "value": "-2.2", "lowerLimit": "-4.2", "upperLimit": "-0.1"}]}]}]}, {"type": "SECONDARY", "title": "Change in Asthma Symptom Utility Index (ASUI)", "description": "A 10-item questionnaire, patient preference-based scale assessing frequency and severity of selected asthma-related symptoms and treatment side effects, for use in clinical trials and cost-effectiveness studies in asthma. Range is 0-1. Higher score is indicative of better health.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "units on a scale", "timeFrame": "baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nPlacebo oral capsule: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}, {"id": "OG001", "title": "Roflumilast", "description": "500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nRoflumilast 500 Mcg Oral Tablet: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": ".14", "lowerLimit": ".07", "upperLimit": ".21"}, {"groupId": "OG001", "value": ".16", "lowerLimit": ".09", "upperLimit": ".23"}]}]}]}, {"type": "SECONDARY", "title": "Change in Gastrointestinal Symptom Rating Scale (GSRS)", "description": "It has 5 subscales (Reflux, Diarrhea, Constipation, Abdominal Pain, and Indigestion Syndrome). Subscale scores range from 1 to 7 and higher scores represent more discomfort and poor health.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "units on scale", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nPlacebo oral capsule: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}, {"id": "OG001", "title": "Roflumilast", "description": "500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nRoflumilast 500 Mcg Oral Tablet: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-.1", "lowerLimit": "-.4", "upperLimit": ".2"}, {"groupId": "OG001", "value": "0.0", "lowerLimit": "-.3", "upperLimit": ".2"}]}]}]}, {"type": "SECONDARY", "title": "Change in Generalized Anxiety Disease (GAD-7)", "description": "GAD-7 has 7 questions. The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and adding together the scores for the seven questions. The following cut-offs correlate with level of anxiety severity:\n\nScore 0-4: Minimal Anxiety Score 5-9: Mild Anxiety Score 10-14: Moderate Anxiety Score greater than 15: Severe Anxiety", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "units on scale", "timeFrame": "baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nPlacebo oral capsule: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}, {"id": "OG001", "title": "Roflumilast", "description": "500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nRoflumilast 500 Mcg Oral Tablet: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-.5", "upperLimit": ".5"}, {"groupId": "OG001", "value": "0.0", "lowerLimit": "-.8", "upperLimit": ".6"}]}]}]}, {"type": "SECONDARY", "title": "Change in Marks Asthma Quality of Life Questionnaire", "description": "20 items with 2 week recall. Self-administered questionnaire intended for use with adults. Respondents are asked to describe how troubling particular items have been over the past four weeks. Covers both physical and emotional impact. Range 1-4. lower score is indicative of better health", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "units on scale", "timeFrame": "baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nPlacebo oral capsule: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}, {"id": "OG001", "title": "Roflumilast", "description": "500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nRoflumilast 500 Mcg Oral Tablet: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-.3", "lowerLimit": "-.6", "upperLimit": "0.0"}, {"groupId": "OG001", "value": "-.4", "lowerLimit": "-.6", "upperLimit": "-.25"}]}]}]}, {"type": "SECONDARY", "title": "Change in SF 36", "description": "The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Range 0-100. Higher score is indicative of better health.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "units on scale", "timeFrame": "baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nPlacebo oral capsule: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}, {"id": "OG001", "title": "Roflumilast", "description": "500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nRoflumilast 500 Mcg Oral Tablet: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.4", "lowerLimit": "2.8", "upperLimit": "10.0"}, {"groupId": "OG001", "value": "5.5", "lowerLimit": "2.5", "upperLimit": "8.6"}]}]}]}, {"type": "SECONDARY", "title": "Change in PHQ9", "description": "The PHQ-9 (Patient Health Questionnaire-9) objectifies and assesses degree of depression severity via questionnaire. It has 9 questions. Range 0-27, lower score is indicate of better health.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "units on scale", "timeFrame": "baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nPlacebo oral capsule: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day."}, {"id": "OG001", "title": "Roflumilast", "description": "500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nRoflumilast 500 Mcg Oral Tablet: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-.6", "lowerLimit": "-1.6", "upperLimit": ".5"}, {"groupId": "OG001", "value": "0.0", "lowerLimit": "-.8", "upperLimit": ".8"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "24 weeks", "eventGroups": [{"id": "EG000", "title": "Placebo Oral Tablet", "description": "500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nPlacebo oral capsule: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.", "deathsNumAffected": 0, "deathsNumAtRisk": 16, "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 10, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Roflumilast 500 mcg Oral Tablet", "description": "500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.\n\nRoflumilast 500 Mcg Oral Tablet: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.", "deathsNumAffected": 0, "deathsNumAtRisk": 22, "seriousNumAffected": 6, "seriousNumAtRisk": 22, "otherNumAffected": 22, "otherNumAtRisk": 22}], "seriousEvents": [{"term": "Asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 22}]}, {"term": "Headache", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 22}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 22}]}, {"term": "Loss of appetite", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 22}]}, {"term": "Dehydration", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 22}]}, {"term": "Abdominal pain (umbilical hernia)", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 22}]}, {"term": "Hyperglycemia", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 22}]}], "otherEvents": [{"term": "Headache", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Treatment emergent", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 22}]}, {"term": "Congestion, runny nose, sneezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Treatment emergent", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 22}]}, {"term": "Acute upper respiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Treatment emergent", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 22}]}, {"term": "Chest discomfort", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 22}]}, {"term": "chest pain", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Treatment emergent", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 22}]}, {"term": "Bloating", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Treatment emergent", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 22}]}, {"term": "Acid reflux", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 22}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Treatment emergent", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 22}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 22}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Treatment emergent", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 22}]}, {"term": "Skin rash", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Treatment emergent", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 22}]}, {"term": "Muscle pain/aches", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Treatment emergent", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 22}]}, {"term": "Any emergent symptoms", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Treatment emergent", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 22}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Gem Roy", "organization": "Johns Hopkins University", "email": "groy2@jhu.edu", "phone": "4432875796"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2020-07-10", "uploadDate": "2022-09-07T15:20", "filename": "Prot_SAP_002.pdf", "size": 478455}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2020-07-10", "uploadDate": "2022-09-07T15:20", "filename": "ICF_003.pdf", "size": 251573}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2022-07-28", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M12701", "name": "Obesity", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}}, "hasResults": true}